[go: up one dir, main page]

GT201300025A - Derivados anticancerosos, su preparación y su aplicación en terapeútica - Google Patents

Derivados anticancerosos, su preparación y su aplicación en terapeútica

Info

Publication number
GT201300025A
GT201300025A GT201300025A GT201300025A GT201300025A GT 201300025 A GT201300025 A GT 201300025A GT 201300025 A GT201300025 A GT 201300025A GT 201300025 A GT201300025 A GT 201300025A GT 201300025 A GT201300025 A GT 201300025A
Authority
GT
Guatemala
Prior art keywords
preparation
therapeutics
application
target derivatives
target
Prior art date
Application number
GT201300025A
Other languages
English (en)
Inventor
Alain Commerçon
Laurence Gauzy-Lazo
Philippe Hubert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43027561&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201300025(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201300025A publication Critical patent/GT201300025A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A CONJUGADOS DE DÍMEROS DE LA PIRROLO[1,4] BENZODIAZEPINA (PBD), A LAS COMPOSICIONES QUE LOS CONTIENEN Y A SU APLICACIÓN TERAPÉUTICA, PRINCIPALMENTE COMO COMPUESTOS ANTICANCEROSOS. LA INVENCIÓN SE REFIERE TAMBIÉN AL PROCEDIMIENTO DE PREPARACIÓN DE LOS CONJUGADOS
GT201300025A 2010-07-26 2013-01-23 Derivados anticancerosos, su preparación y su aplicación en terapeútica GT201300025A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1056103A FR2963007B1 (fr) 2010-07-26 2010-07-26 Derives anticancereux, leur preparation et leur application therapeutique

Publications (1)

Publication Number Publication Date
GT201300025A true GT201300025A (es) 2014-07-11

Family

ID=43027561

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300025A GT201300025A (es) 2010-07-26 2013-01-23 Derivados anticancerosos, su preparación y su aplicación en terapeútica

Country Status (31)

Country Link
US (1) US9056914B2 (es)
EP (1) EP2598507B1 (es)
JP (1) JP5814366B2 (es)
KR (1) KR20130094806A (es)
CN (1) CN103140491B (es)
AR (1) AR082341A1 (es)
AU (1) AU2011284339B2 (es)
BR (1) BR112013001978B1 (es)
CA (1) CA2806665A1 (es)
CL (1) CL2013000250A1 (es)
CO (1) CO6650375A2 (es)
CR (1) CR20130035A (es)
DO (1) DOP2013000021A (es)
EA (1) EA201390162A1 (es)
EC (1) ECSP13012404A (es)
ES (1) ES2638520T3 (es)
FR (1) FR2963007B1 (es)
GT (1) GT201300025A (es)
MA (1) MA34469B1 (es)
MX (1) MX2013001069A (es)
MY (1) MY159197A (es)
NI (1) NI201300010A (es)
NZ (1) NZ606246A (es)
PE (1) PE20130489A1 (es)
PH (1) PH12013500154A1 (es)
SG (1) SG187191A1 (es)
TW (1) TW201208689A (es)
UA (1) UA111164C2 (es)
UY (1) UY33531A (es)
WO (1) WO2012014147A1 (es)
ZA (1) ZA201300685B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949469A1 (fr) * 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
JP5993093B2 (ja) 2012-10-12 2016-09-14 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン類およびその複合体
WO2014159981A2 (en) * 2013-03-13 2014-10-02 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
AU2014229529B2 (en) * 2013-03-13 2018-02-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
PE20170935A1 (es) 2014-09-12 2017-07-13 Genentech Inc Anticuerpos anti-her2 e inmunoconjugados
BR112017004953A2 (pt) * 2014-09-17 2017-12-05 Genentech Inc imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
CN107428780B (zh) 2015-01-14 2020-09-04 百时美施贵宝公司 苯并二氮杂*二聚体、其缀合物及制备和使用方法
JP6676058B2 (ja) 2015-01-14 2020-04-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
CN108391434A (zh) 2015-06-23 2018-08-10 百时美施贵宝公司 大环苯并二氮杂*二聚体、其缀合物、制备和用途
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
HUE054689T2 (hu) 2017-02-08 2021-09-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
SI3612537T1 (sl) 2017-04-18 2022-10-28 Medimmune Limited Konjugati pirolobenzodiazepina
SG11202000358YA (en) 2017-08-18 2020-02-27 Medimmune Ltd Pyrrolobenzodiazepine conjugates
TWI885539B (zh) 2017-09-29 2025-06-01 日商第一三共股份有限公司 抗體－吡咯并苯二氮呯衍生物複合體
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
CN115466231B (zh) * 2022-10-23 2024-03-08 浙江大学 管道化制备3-[2-(4-吗啉基)乙氧基]丙腈的方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516743A (fr) 1966-04-01 1968-02-05 Rhone Poulenc Sa Nouvel antibiotique et son procédé de préparation par culture de streptomyces croceus
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
WO1990006774A1 (en) 1988-12-22 1990-06-28 Xoma Corporation Hindered linking agents and methods
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE69907977T2 (de) 1998-08-27 2004-07-22 Spirogen Ltd., Ryde Pyrrolobenzodiazepine
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
ATE499116T1 (de) 2002-08-16 2011-03-15 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
BR0316101A (pt) 2002-11-07 2005-09-27 Immunogen Inc Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
CA2525130C (en) 2003-05-20 2014-04-15 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
WO2005009369A2 (en) 2003-07-21 2005-02-03 Immunogen, Inc. A ca6 antigen-specific cytotoxic conjugate and methods of using the same
ATE516288T1 (de) 2003-10-22 2011-07-15 Us Gov Health & Human Serv Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
GB0404577D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
US7528126B2 (en) 2004-03-09 2009-05-05 Spirogen Limited Pyrrolobenzodiazepines
EP1669358A1 (en) 2004-12-07 2006-06-14 Aventis Pharma S.A. Cytotoxic agents comprising new taxanes
US7638491B2 (en) 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
EP1813614B1 (en) * 2006-01-25 2011-10-05 Sanofi Cytotoxic agents comprising new tomaymycin derivatives
DE112007000079B4 (de) * 2006-02-13 2015-08-13 Council Of Scientific & Industrial Research Neuartige Bis-Pyrrolo[2,1-c][1,4]benzodiazepin-anthrachinon Konjugate und ein Verfahren zu deren Herstellung
EP1832577A1 (en) 2006-03-07 2007-09-12 Sanofi-Aventis Improved prodrugs of CC-1065 analogs
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
WO2008010101A2 (en) 2006-07-18 2008-01-24 Sanofi-Aventis Antagonist antibody against epha2 for the treatment of cancer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
PT2019104E (pt) * 2007-07-19 2013-12-03 Sanofi Sa Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
EP2276506A4 (en) 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
CN104524590B (zh) 2008-04-30 2019-06-21 伊缪诺金公司 交联剂和它们的用途
FR2939795B1 (fr) 2008-12-17 2010-12-17 Sanofi Aventis Procede de preparation d'esters actives
AU2010210646B2 (en) * 2009-02-05 2015-10-29 Immunogen, Inc. Novel benzodiazepine derivatives
AR078471A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS

Also Published As

Publication number Publication date
KR20130094806A (ko) 2013-08-26
AR082341A1 (es) 2012-11-28
MA34469B1 (fr) 2013-08-01
FR2963007A1 (fr) 2012-01-27
CL2013000250A1 (es) 2013-04-12
EA201390162A1 (ru) 2013-11-29
BR112013001978B1 (pt) 2020-03-03
DOP2013000021A (es) 2013-04-15
FR2963007B1 (fr) 2013-04-05
EP2598507B1 (en) 2017-05-31
US20130137659A1 (en) 2013-05-30
US9056914B2 (en) 2015-06-16
NI201300010A (es) 2013-05-13
PH12013500154A1 (en) 2013-02-18
MX2013001069A (es) 2013-12-02
JP5814366B2 (ja) 2015-11-17
MY159197A (en) 2016-12-30
TW201208689A (en) 2012-03-01
PE20130489A1 (es) 2013-05-08
WO2012014147A1 (en) 2012-02-02
CN103140491A (zh) 2013-06-05
CA2806665A1 (en) 2012-02-02
CO6650375A2 (es) 2013-04-15
CR20130035A (es) 2013-03-04
AU2011284339B2 (en) 2015-11-05
AU2011284339A1 (en) 2013-02-14
ES2638520T3 (es) 2017-10-23
EP2598507A1 (en) 2013-06-05
JP2013532680A (ja) 2013-08-19
NZ606246A (en) 2015-04-24
BR112013001978A2 (pt) 2016-05-24
SG187191A1 (en) 2013-02-28
UA111164C2 (uk) 2016-04-11
ECSP13012404A (es) 2013-03-28
CN103140491B (zh) 2016-08-10
UY33531A (es) 2012-02-29
ZA201300685B (en) 2014-10-29

Similar Documents

Publication Publication Date Title
GT201300025A (es) Derivados anticancerosos, su preparación y su aplicación en terapeútica
CO6612210A2 (es) Conjugados de dimeros de pirrolo(1.4) benzodiazepina como agentes anticancerosos
CR20130001A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
MX375715B (es) Profarmacos de metilfenidato, procesos de elaboración y uso de los mismos.
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
ECSP088632A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina
UA118177C2 (uk) Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну
CR11623A (es) Compuestos
AR076196A1 (es) Anticuerpos biespecificos anti-erbb-3/anti-c-met
CO6511271A2 (es) Compuestos de imidazopiridinil-aminopiridina sustituida
SV2011003855A (es) Heteroarilos sustituidos
GT201200307A (es) NUEVOS DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENÉRGICOS ß2 Y COMO ANTAGONISTAS MUSCARÍNICOS M3
ECSP11011340A (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen
CR20130671A (es) Antagonistas de trpv4
ECSP11010834A (es) Formulaciones farmacéuticas que contienen ligandos de receptores de dopamina
CR10247A (es) Dimeros de derivados de artemisinina, su preparacion y su aplicacion en terapeutica
SV2011003800A (es) Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica
CR20120542A (es) HETEROARIL-CICLOHEXIL-TETRAAZABENZO [e] AZULENOS
UY32517A (es) Derivados de nicotinamida, su preparación y su aplicación en terapéutica
GT200900192A (es) Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).-
SV2009003429A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
BR112013025236A2 (pt) derivados de tieno [2,3-d)pirimidina e seu uso no tratamento de arritmia
BR112013012719A2 (pt) "compostos como moduladores de receptor com utilidade terapêutica".